caa a22 4500 605490996 CHVBK 20210128100507.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0746-7 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0746-7 Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer [Elektronische Daten] [Keisuke Shigeta, Takeo Kosaka, Satoshi Yazawa, Yota Yasumizu, Ryuichi Mizuno, Hirohiko Nagata, Kazunobu Shinoda, Shinya Morita, Akira Miyajima, Eiji Kikuchi, Ken Nakagawa, Shintaro Hasegawa, Mototsugu Oya] Background: The aim of this study is to identify factors that increase the occurrence of severe neutropenia (SN) and febrile neutropenia (FN) during docetaxel treatment for castration-resistant prostate cancer (CRPC). Methods: We retrospectively reviewed 258 courses during the first three cycles among 95 patients. Docetaxel at a dose of 75mg/m2 was administered every 3 or 4weeks. Patient background, laboratory data, and bone scan results were collected to assess predictive factors for SN and FN. We defined SN as an absolute neutrophil count (ANC)of <500/mm3 and defined FN as an ANCof <1000/mm3 with a body temperature of >38.3°C. Results: The mean age of the patients was 72.6±6.4 years and the mean prostate-specific antigen was 135.4±290.9ng/ml. During the first three courses of treatment, SN occurred in 72.6% of patients and FN occurred in 9.5% of patients. Univariate analysis demonstrated that age≥75 years (p=0.002), number of comorbidities≥1.2 (p=0.008 and p=0.006) and previous external beam radiation therapy (EBRT) (p=0.001) were predictive factors for the development of SN or FN. In multivariate analysis, significant predictors of SN or FN were age≥75 years (hazard ratio [HR] 5.77; p=0.004) and previous EBRT (HR 14.5; p=0.012). According to the subgroup analysis dividing SN and FN separately, multivariate analysis also revealed that age≥75 years and previous EBRT were also significant predictors for developing SN (HR 5.09; p=0.023, HR 12.7; p=0.020, respectively) and for developing FN (HR 5.45; p=0.042, HR 7.72; p=0.015, respectively). Conclusions: Patients aged≥75years and with a history of localized radiation therapy are at higher risk for significant neutropenic events and require closer surveillance. Japan Society of Clinical Oncology, 2014 Severe neutropenia nationallicence Febrile neutropenia nationallicence Docetaxel nationallicence Predictive factor nationallicence Castration-resistant prostate cancer nationallicence Shigeta Keisuke Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Kosaka Takeo Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Yazawa Satoshi Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Yasumizu Yota Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Mizuno Ryuichi Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Nagata Hirohiko Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Shinoda Kazunobu Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Morita Shinya Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Miyajima Akira Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Kikuchi Eiji Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Nakagawa Ken Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Hasegawa Shintaro Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Oya Mototsugu Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 605-612 1341-9625 20:3<605 2015 20 10147 https://doi.org/10.1007/s10147-014-0746-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0746-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Shigeta Keisuke Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Kosaka Takeo Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Yazawa Satoshi Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Yasumizu Yota Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Mizuno Ryuichi Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Nagata Hirohiko Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Shinoda Kazunobu Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Morita Shinya Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Miyajima Akira Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Kikuchi Eiji Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Nakagawa Ken Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Hasegawa Shintaro Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Oya Mototsugu Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 605-612 1341-9625 20:3<605 2015 20 10147